~ 712 ~ The Pharma Innovation Journal 2018; 7(10): 712-715 ISSN (E): 2277- 7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(10): 712-715 © 2018 TPI www.thepharmajournal.com Received: 22-08-2018 Accepted: 26-09-2018 Satish D Patel Zydus Research Centre, Cadila Healthcare Ltd., Ahmedabad, Gujarat, India Urvesh D Patel College of Veterinary Science and Animal Husbandry, Junagadh Agricultural University, Junagadh, Gujarat, India Kamlesh A Sadariya College of Veterinary Science and Animal Husbandry, Anand Agricultural University, Anand, Gujarat, India Aswin M Thaker College of Veterinary Science and Animal Husbandry, Anand Agricultural University, Anand, Gujarat, India Shailesh K Bhavsar College of Veterinary Science and Animal Husbandry, Anand Agricultural University, Anand, Gujarat, India Correspondence Satish D Patel Zydus Research Centre, Cadila Healthcare Ltd., Ahmedabad, Gujarat, India Blood biochemical profile following administration of erlotinib, meloxicam and metformin alone and in combination in SCID mice Satish D Patel, Urvesh D Patel, Kamlesh A Sadariya, Aswin M Thaker and Shailesh K Bhavsar Abstract The study was carried out to evaluate blood biochemical profile following administration of erlotinib, meloxicam and metformin alone and in combination in SCID mice. The mean value of WBC of animal group treated by erlotinib with metformin was significantly increased in comparison to tumor control group. The neutrophil % of tumor control and all treatment groups was considerably high in comparison to normal control, whereas the lymphocyte % and eosinophil % count were decreased in tumor control and treatment group in comparison to normal control. The monocyte % count in animal group treated by metformin alone and in combination with erlotinib was significantly higher than tumor control group. The mean value of creatine kinase (CK) was significantly decreased in animal group treated with meloxicam in comparison to tumor control group. Whereas, the mean value of CK and blood urea nitrogen (BUN) of animal group treated with erlotinib with metformin was significantly increased in comparison to tumor control group. Raised level of BUN in present study might be due to additive damaging effect of metformin and erlotinib on kidney. The mean values of AST, ALT, TB and acid phosphatase of tumor control group were considerably high than normal control group. The mean values of ALP, total bilirubin, creatinine, and acid phosphatase did not alter. In conclusion, administration of erlotinib, meloxicam and metformin in combination alter blood biochemical profile in SCID mice. Keywords: Haematology, biochemical parameters, erlotinib, meloxicam, metformin, SCID mice 1. Introduction Erlotinib, a selective EGFR- TK inhibitor is used for treatment of cancer. Erlotinib is a highly potent, orally active inhibitor of HER1/EGFR -TK thereby, prevents phosphorylation of the receptors and the subsequent cascade of signaling events [1] . Meloxicam is a selective COX-2 inhibitor, which has been tested for its chemopreventive effects in bladder cancer but not in other types of cancer [2] . Metformin is the most widely used antidiabetic drug and there is increasing evidence of a potential efficacy of this agent as an anticancer drug. Metformin activates the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer [3] . Mono and combination therapeutic approaches have also been studied and employed to treat or inhibit growth of tumor (adenocarcinoma) in animal models (eg. Xenograft mice model) and clinical cases of human cancer. Pharmacokinetic interaction of erlotinin, meloxicam and metformin was also evaluated in SCID mice [4, 5, 6] . The effect of administration of erlotinib, meloxicam and metformin alone and in combination on blood biochemical parameters in rodent was not studied so far. Thus, present study was planned to evaluate blood biochemical profile following administration of erlotinib, meloxicam and metformin alone and in combination in tumor bearing SCID mice 2. Materials and Methods 2.1 Experimental animals and conditions Fifty four healthy male SCID mice of 5-8 weeks of age were used to conduct the study which were procured from and maintained at Animal Research Facility, Zydus Research Centre, Cadila Healthcare Ltd., Ahmedabad, India. Sterilized conventional polypropylene cages in animal isolators were used to house all mice in groups of 3 mice. Gamma irradiated laboratory animal diet (Teklad 18, Rodent Pellet feed, Harlan laboratories, USA) and purified autoclaved